Page 75«..1020..72737475

CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis

By Dr. Matthew Watson

CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis

Link:
CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis

To Read More: CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis
categoriaGlobal News Feed commentoComments Off on CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis | dataOctober 17th, 2020
Read All

Aimmune Receives Positive CHMP Opinion on PALFORZIA® for the Treatment of Patients with Peanut Allergy in Europe

By Dr. Matthew Watson

Final European Commission Decision on Marketing Approval Anticipated in Q4 2020 Final European Commission Decision on Marketing Approval Anticipated in Q4 2020

Continued here:
Aimmune Receives Positive CHMP Opinion on PALFORZIA® for the Treatment of Patients with Peanut Allergy in Europe

To Read More: Aimmune Receives Positive CHMP Opinion on PALFORZIA® for the Treatment of Patients with Peanut Allergy in Europe
categoriaGlobal News Feed commentoComments Off on Aimmune Receives Positive CHMP Opinion on PALFORZIA® for the Treatment of Patients with Peanut Allergy in Europe | dataOctober 17th, 2020
Read All

Beyond Air® Presents Positive New Preclinical Data for the Use of a Single Injection of Gaseous Nitric Oxide as a Novel In situ Cancer Vaccination

By Dr. Matthew Watson

GARDEN CITY, N.Y., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced new in vitro and in vivo preclinical data that suggest the Company’s innovative gNO-based treatment may treat lung cancer locally and its metastases systemically, potentially via stimulation of an anti-tumor immune response. These data were included in a presentation by Hila Confino, PhD of Beyond Air at the International Association for the Study of Lung Cancer’s (IASLC) North America Conference on Lung Cancer 2020 (NACLC 2020), which is being held from October 16th to 17th.

Read the original:
Beyond Air® Presents Positive New Preclinical Data for the Use of a Single Injection of Gaseous Nitric Oxide as a Novel In situ Cancer Vaccination

To Read More: Beyond Air® Presents Positive New Preclinical Data for the Use of a Single Injection of Gaseous Nitric Oxide as a Novel In situ Cancer Vaccination
categoriaGlobal News Feed commentoComments Off on Beyond Air® Presents Positive New Preclinical Data for the Use of a Single Injection of Gaseous Nitric Oxide as a Novel In situ Cancer Vaccination | dataOctober 17th, 2020
Read All

Zogenix Receives Positive CHMP Opinion for FINTEPLA® (Fenfluramine) Oral Solution for the Treatment of Seizures in Patients with Dravet Syndrome

By Dr. Matthew Watson

EMERYVILLE, Calif., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that the Committee for Medicinal Products for Human Use (CHMP), a part of the European Medicines Agency (EMA), has adopted a positive opinion recommending the marketing authorization of FINTEPLA® (fenfluramine) oral solution for the treatment of seizures associated with Dravet syndrome, a rare and devastating infant- and childhood onset epilepsy, as an add-on therapy to other antiepileptic medicines for patients two years of age and older. The European Commission (EC) is expected to make a final decision on the company’s Marketing Authorization Application (MAA) by the end of the year.

Read this article:
Zogenix Receives Positive CHMP Opinion for FINTEPLA® (Fenfluramine) Oral Solution for the Treatment of Seizures in Patients with Dravet Syndrome

To Read More: Zogenix Receives Positive CHMP Opinion for FINTEPLA® (Fenfluramine) Oral Solution for the Treatment of Seizures in Patients with Dravet Syndrome
categoriaGlobal News Feed commentoComments Off on Zogenix Receives Positive CHMP Opinion for FINTEPLA® (Fenfluramine) Oral Solution for the Treatment of Seizures in Patients with Dravet Syndrome | dataOctober 17th, 2020
Read All

Spero Therapeutics to Present Data for All Pipeline Programs at IDWeek 2020

By Dr. Matthew Watson

15 data presentations cover each of Spero’s three pipeline programs and include a late breaker oral presentation on the Phase 3 ADAPT-PO clinical trial 15 data presentations cover each of Spero’s three pipeline programs and include a late breaker oral presentation on the Phase 3 ADAPT-PO clinical trial

View original post here:
Spero Therapeutics to Present Data for All Pipeline Programs at IDWeek 2020

To Read More: Spero Therapeutics to Present Data for All Pipeline Programs at IDWeek 2020
categoriaGlobal News Feed commentoComments Off on Spero Therapeutics to Present Data for All Pipeline Programs at IDWeek 2020 | dataOctober 17th, 2020
Read All

Psychedelics Experiencing Renaissance, Offer Tremendous Treatment Potential

By Dr. Matthew Watson

NEW YORK, Oct. 16, 2020 (GLOBE NEWSWIRE) -- NetworkNewsAudio -- Cybin Corp. announces the availability of a broadcast titled, “Multi-Billion-Dollar Market Forecast in Psychedelic Therapeutics.”

Read more here:
Psychedelics Experiencing Renaissance, Offer Tremendous Treatment Potential

To Read More: Psychedelics Experiencing Renaissance, Offer Tremendous Treatment Potential
categoriaGlobal News Feed commentoComments Off on Psychedelics Experiencing Renaissance, Offer Tremendous Treatment Potential | dataOctober 17th, 2020
Read All

SPACs Show Investors Faster, Simpler Way to Go Public

By Dr. Matthew Watson

NEW YORK, Oct. 16, 2020 (GLOBE NEWSWIRE) -- NetworkNewsAudio -- 180 Life Sciences Corp. announces the availability of a broadcast titled, “Blockbuster Year and Bright Horizons for SPACs.”

See original here:
SPACs Show Investors Faster, Simpler Way to Go Public

To Read More: SPACs Show Investors Faster, Simpler Way to Go Public
categoriaGlobal News Feed commentoComments Off on SPACs Show Investors Faster, Simpler Way to Go Public | dataOctober 17th, 2020
Read All

German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test

By Dr. Matthew Watson

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

View post:
German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test

To Read More: German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test
categoriaGlobal News Feed commentoComments Off on German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test | dataOctober 17th, 2020
Read All

Y-mAbs Announces Update on Naxitamab and Omburtamab in Neuroblastoma

By Dr. Matthew Watson

NEW YORK, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced clinical updates on naxitamab for the treatment of relapsed/refractory high-risk neuroblastoma and omburtamab for CNS/leptomeningeal metastasis from neuroblastoma. Data was presented at the International Society of Pediatric Oncology (“SIOP”) Virtual Annual Congress held October 14 through October 17, 2020 in Ottawa, Canada. The naxitamab data was presented by Dr. Jaume Mora from SJD Barcelona Children's Hospital, and the omburtamab data was presented by Dr. Kim Kramer from Memorial Sloan Kettering Cancer Center (“MSK”).

More here:
Y-mAbs Announces Update on Naxitamab and Omburtamab in Neuroblastoma

To Read More: Y-mAbs Announces Update on Naxitamab and Omburtamab in Neuroblastoma
categoriaGlobal News Feed commentoComments Off on Y-mAbs Announces Update on Naxitamab and Omburtamab in Neuroblastoma | dataOctober 17th, 2020
Read All

Biomerica Reports Fiscal 2021 1st Quarter Financial Results

By Dr. Matthew Watson

IRVINE, Calif., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported financial results for the fiscal quarter ended August 31, 2020.

See more here:
Biomerica Reports Fiscal 2021 1st Quarter Financial Results

To Read More: Biomerica Reports Fiscal 2021 1st Quarter Financial Results
categoriaGlobal News Feed commentoComments Off on Biomerica Reports Fiscal 2021 1st Quarter Financial Results | dataOctober 17th, 2020
Read All

Stabilization measures taken

By Dr. Matthew Watson

Orphazyme A/SCompany announcement                                                                                       No. 66/2020                                                                                                           Company Registration No. 32266355

Read this article:
Stabilization measures taken

To Read More: Stabilization measures taken
categoriaGlobal News Feed commentoComments Off on Stabilization measures taken | dataOctober 17th, 2020
Read All

Coherus BioSciences Announces New Employment Inducement Grants

By Dr. Matthew Watson

REDWOOD CITY, Calif., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective October 15, 2020, the compensation committee of the Company’s board of directors granted a newly hired Executive Vice President an option to buy 150,000 shares of the Company’s common stock with a per share exercise price of $18.09, the closing trading price on the grant date, and 10,000 restricted stock units.

More here:
Coherus BioSciences Announces New Employment Inducement Grants

To Read More: Coherus BioSciences Announces New Employment Inducement Grants
categoriaGlobal News Feed commentoComments Off on Coherus BioSciences Announces New Employment Inducement Grants | dataOctober 17th, 2020
Read All

Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute…

By Dr. Matthew Watson

– Agios Continues to Advance Two Phase 3 Combination Trials of TIBSOVO® in Newly Diagnosed AML Patients –

Here is the original post:
Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute...

To Read More: Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute…
categoriaGlobal News Feed commentoComments Off on Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute… | dataOctober 17th, 2020
Read All

Eton Pharmaceuticals Announces Closing of Public Offering

By Dr. Matthew Watson

DEER PARK, Ill., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the closing of its previously announced offering of 3,220,000 shares of common stock at a public offering price of $7.00 per share. The total offering included 420,000 shares sold as a result of the underwriter’s exercise of its overallotment option in full.

Visit link:
Eton Pharmaceuticals Announces Closing of Public Offering

To Read More: Eton Pharmaceuticals Announces Closing of Public Offering
categoriaGlobal News Feed commentoComments Off on Eton Pharmaceuticals Announces Closing of Public Offering | dataOctober 17th, 2020
Read All

Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange

By Dr. Matthew Watson

VANCOUVER, British Columbia, Oct. 16, 2020 (GLOBE NEWSWIRE) -- MYDECINE INNOVATIONS GROUP, INC., (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”) is pleased to announce the appointment of UK-based Boustead Capital Markets LLP (“Boustead”) to commence the dual listing process on the London Stock Exchange (“LSE” or the “Exchange”) for the admission of the Company’s common shares to the Standard Segment of the Official List’s Main Market.

See original here:
Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange

To Read More: Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange
categoriaGlobal News Feed commentoComments Off on Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange | dataOctober 17th, 2020
Read All

Page 75«..1020..72737475